TRILINK BIOTECHNOLOGIES LLC, headquartered in the United States, is a leading player in the biotechnology industry, specialising in nucleic acid synthesis and related services. Founded in 2000, the company has established itself as a trusted partner for researchers and organisations across the globe, with a strong operational presence in North America and Europe. TRILINK offers a diverse range of core products, including custom oligonucleotides, RNA synthesis, and modified nucleotides, all designed to meet the evolving needs of the scientific community. Their commitment to quality and innovation sets them apart, ensuring that clients receive superior products tailored to their specific applications. With a reputation for excellence, TRILINK has achieved significant milestones, solidifying its position as a preferred supplier in the biotechnology sector.
How does TRILINK BIOTECHNOLOGIES LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
TRILINK BIOTECHNOLOGIES LLC's score of 29 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
TriLink BioTechnologies LLC, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Maravai LifeSciences Holdings, Inc., which may influence its climate commitments and reporting practices. As of now, TriLink BioTechnologies has not established any documented reduction targets or climate pledges. The lack of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given its affiliation with Maravai LifeSciences, any potential climate commitments or emissions data may be inherited from this parent company. However, no specific details regarding emissions or reduction targets from Maravai LifeSciences have been provided in the available data. In summary, while TriLink BioTechnologies LLC has not disclosed any emissions data or reduction initiatives, its relationship with Maravai LifeSciences may play a role in shaping its future climate commitments.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 330,000 | 000,000 | 000,000 | 000,000 | 
| Scope 2 | 1,103,000 | 0,000,000 | 0,000,000 | 0,000,000 | 
| Scope 3 | - | - | 00,000,000 | 00,000,000 | 
TRILINK BIOTECHNOLOGIES LLC's Scope 3 emissions, which increased by 232% last year and increased by approximately 232% since 2023, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 77% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
TRILINK BIOTECHNOLOGIES LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.